^
    6d
    In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma. (PubMed, Gastroenterol Rep (Oxf))
    In addition, plasma proteins were significantly associated with survival outcomes, whereas no significant association was observed between clinical variables and prognosis. Plasma proteomics not only captured CAR-GPC3-driven plasma microenvironment remodeling but also identified baseline proteins predictive of CB and survival, which were superior to clinical variables, thus constituting a candidate biomarker panel for HCC patient selection and response monitoring.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • GPC3 (Glypican 3)
    |
    CT0180
    9d
    DUET-1: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=7, Active, not recruiting, Sotio Biotech Inc. | Trial primary completion date: Oct 2027 --> Oct 2025
    Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation
    |
    cyclophosphamide • BOXR1030
    26d
    Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=24, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • fludarabine IV
    27d
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Baylor College of Medicine | N=24 --> 14
    Enrollment change
    |
    GPC3 (Glypican 3) • IL15 (Interleukin 15)
    |
    AGAR T cells
    1m
    INTERCEPT: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial
    2ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Feb 2040 --> Aug 2040
    Enrollment closed • Trial completion date
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    3ms
    CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, Zhejiang University | Trial completion date: Jun 2024 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • GPC3 (Glypican 3)
    |
    cyclophosphamide • CT0180
    4ms
    IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial
    4ms
    Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV
    4ms
    DUET-1: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=7, Active, not recruiting, Sotio Biotech Inc. | Recruiting --> Active, not recruiting | N=110 --> 7
    Enrollment closed • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation
    |
    cyclophosphamide • BOXR1030
    5ms
    Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3-CAR and IL15 plus IL21
    5ms
    BAH2573-104: Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Essen Biotech
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV